XML 17 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Income Statement [Abstract]        
Revenue $ 47 $ 94
Cost of revenues 95 156 50
Gross loss (48) (62) (50)
Operating expenses:        
Research and development 987 1,499 2,445 3,173
General and administrative 3,896 2,590 8,211 6,182
Acquisition of Exacis in-process research and development 460 460
Total operating expenses 4,883 4,549 10,656 9,815
Loss from operations (4,931) (4,549) (10,718) (9,865)
Other (expense) income, net:        
Change in fair value of warrant liabilities 136 191 66 146
Change in fair value of contingent consideration 66 118 66 118
Loss on non-controlling investment (8) (59)
Interest (expense) income, net (797) 24 (1,583) 25
Other expense, net (280) (280)
Total other (expense) income, net (595) 45 (1,451) (50)
Loss before income taxes (5,526) (4,504) (12,169) (9,915)
Provision for income taxes (3) (4) (7) (9)
Net loss (5,529) (4,508) (12,176) (9,924)
Series A preferred stock dividend (8) (8) (8) (8)
Net loss attributable to common stockholders $ (5,537) $ (4,516) $ (12,184) $ (9,932)
Net loss per common share - basic $ (1.02) $ (0.85) $ (2.25) $ (1.90)
Net loss per common share - diluted $ (1.02) $ (0.85) $ (2.25) $ (1.90)
Weighted average shares outstanding - basic 5,410 5,303 5,410 5,215
Weighted average shares outstanding - diluted 5,410 5,303 5,410 5,215